{"id":"oral-norfloxacin","safety":{"commonSideEffects":[{"rate":"3-11%","effect":"Nausea"},{"rate":"2-8%","effect":"Diarrhea"},{"rate":"2-7%","effect":"Headache"},{"rate":"1-5%","effect":"Dizziness"},{"rate":"1-4%","effect":"Abdominal pain"},{"rate":"1-3%","effect":"Photosensitivity"},{"rate":"<1%","effect":"Tendinitis/tendon rupture"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Norfloxacin works by binding to and inhibiting DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This leads to accumulation of DNA breaks, cell death, and bactericidal activity. The oral formulation allows systemic absorption for treatment of various bacterial infections.","oneSentence":"Norfloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:21.669Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Urinary tract infections (uncomplicated and complicated)"},{"name":"Bacterial prostatitis"},{"name":"Gastrointestinal infections"},{"name":"Respiratory tract infections"}]},"trialDetails":[{"nctId":"NCT03479736","phase":"","title":"A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting","enrollment":117911},{"nctId":"NCT05667818","phase":"PHASE1","title":"An Comparative Pharmacokinetic Study of Amlodipine Besylate Controlled-release Tablets,China in Normal, Healthy, Adult, Human Subjects Under Fasting Conditions","status":"UNKNOWN","sponsor":"Overseas Pharmaceuticals, Ltd.","startDate":"2023-01-28","conditions":"Hypertension","enrollment":16},{"nctId":"NCT05621005","phase":"PHASE2","title":"Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients","status":"COMPLETED","sponsor":"Samar Atef Sebaweh Mohammed","startDate":"2019-03-01","conditions":"Ascites Infection","enrollment":104},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04621617","phase":"PHASE3","title":"Midodrine and Albumin in Patients With Refractory Ascites","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2020-11","conditions":"Refractory Ascites","enrollment":114},{"nctId":"NCT03702426","phase":"NA","title":"Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2018-07-23","conditions":"Spontaneous Bacterial Peritonitis","enrollment":120},{"nctId":"NCT03506256","phase":"PHASE4","title":"Noroxin Efficacy and Safety Trial","status":"UNKNOWN","sponsor":"OBS Pakistan","startDate":"2018-05-10","conditions":"Urinary Tract Infections","enrollment":1000},{"nctId":"NCT01037959","phase":"PHASE3","title":"Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-04","conditions":"Cirrhosis","enrollment":291},{"nctId":"NCT01527019","phase":"PHASE3","title":"Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2012-10","conditions":"Cystitis","enrollment":""},{"nctId":"NCT01881438","phase":"","title":"An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2000-01","conditions":"Retinal Detachment","enrollment":119924},{"nctId":"NCT00359853","phase":"PHASE4","title":"Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2000-09","conditions":"Spontaneous Bacterial Peritonitis, Hepatorenal Syndrome, Cirrhosis","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":53,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oral norfloxacin","genericName":"Oral norfloxacin","companyName":"Hospital Clinic of Barcelona","companyId":"hospital-clinic-of-barcelona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Norfloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Urinary tract infections (uncomplicated and complicated), Bacterial prostatitis, Gastrointestinal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}